ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
15 announcements with these filters
GKB Ophthalmics filed minutes of its 44th AGM held on 25 August 2026. It approved financial statements and re-appointed directors, declaring no dividend due to operating losses.
GKB Ophthalmics Ltd held its 44th Annual General Meeting on August 25, 2026. Key resolutions included financial statement adoption and re-appointment of senior directors.
GKB Ophthalmics Ltd reported revenue from operations of ₹33 Cr (+2.2% YoY) and net profit of ₹1.8 Cr for Q1 FY27.
GKB Ophthalmics has provided shareholders with a web-link to access the Annual Report for F.Y. 2025-26, fulfilling Regulation 36(1)(b) disclosure requirements.
GKB Ophthalmics Ltd has announced its 44th Annual General Meeting for August 25, 2026. Consequently, the Register of Members will be closed from August 19 to August 25.
GKB Ophthalmics Ltd. submitted its 44th Annual Report and AGM notice for the financial year 2025-26. The meeting is scheduled for August 25, 2026, at its registered office.
GKB Ophthalmics Ltd. has scheduled a board meeting on August 12, 2026, to consider and approve its unaudited standalone and consolidated financial results.
GKB Ophthalmics received a ₹8.82 Crore demand notice following a labor tribunal award. The company intends to challenge this order before the Bombay High Court.
Krishna Gopal Gupta & Sons (HUF) bought 1,016 shares of GKB Ophthalmics for ₹64,801.77. The purchase is disclosed as per SEBI PIT regulations.
GKB Ophthalmics reported a consolidated annual income of ₹151.31 Crore for FY2026. The results, audited by MSKA & Associates, reflect the company's full-year financial performance.
GKB Ophthalmics Ltd reported revenue from operations of ₹29.8 Cr (-3.9% YoY) and net profit of ₹1.1 Cr for Q4 FY26.
GKB Ophthalmics approved audited standalone and consolidated financial results for fiscal year 2026. The board decided to skip dividends and re-appointed internal auditors.
CRISIL migrated GKB Ophthalmics' rating from 'Issuer Not Cooperating' to 'Crisil D' for ₹15.1 Crore bank facilities. This reflects continued financial stress and weak protection metrics.
GKB Ophthalmics Ltd filed its Annual Secretarial Compliance Report for FY2026. The report confirms overall regulatory adherence, including a previously waived fine of ₹2,360.
GKB Ophthalmics Ltd has scheduled a Board Meeting for May 27, 2026, to approve audited standalone and consolidated financial results for the year ended March 31, 2026. Consequently, the trading window for dealing in company shares has been closed from April 01, 2026, until 48 hours after the results are submitted.